Therapy Areas: Vaccines
Dr. Reddy's Laboratories awarded DCGI's EUA for use of Sputnik V in India in the battle against COVID-19
13 April 2021 -

Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) announced on Tuesday that it has received permission from the Drug Controller General of India (DCGI) to import Russia's Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules 2019 under the Drugs and Cosmetics Act.

Dr. Reddy's conducted the clinical trials of Sputnik V in Russia and will distribute the vaccine in India, under a 2020 partnership with the Russian Direct Investment Fund (RDIF),

In conjunction with the trials conducted in Russia by RDIF, the company also carried out Phase II / III clinical trials of the vaccine in India.

The company added that Sputnik V is now approved for use in 60 countries around the world. It ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators. It uses two different vectors for the two shots in a course of vaccination. The efficacy of the vaccine was determined to be 91.6% in an article published in respected medical journal the Lancet.